Subcutaneous lisuride infusion Parkinson disease Response administration patients Thirty-eight parkinsonian patients motor fluctuations dyskinesias chronic levodopa therapy subcutaneous lisuride infusion SLI hospital combined treatment lisuride infusion micrograms/h oral levodopa decarboxylase inhibitor mg/day marked initial improvement mobility mean reduction hours mean months patients improvement respect assessment chronic treatment dyskinesias periods difficult levodopa schedule dose patients lisuride treatment inefficacy high incidence psychiatric side-effects major factor lisuride infusion population severe parkinsonian patients Many inconvenience pump technical requirements long-term utilization patients SLI reason results motor function severe parkinsonian patients SLI dyskinesia psychiatric adverse effects long-term usefulness approach continuous dopaminergic stimulation useful therapeutic strategy stages disease 